|
 |
European Pharmaceutical Contractor
|
| In the wake of unusual adverse cardiac reactions to everyday drugs, Jean Barbey at Medifacts International assesses how and why we measure the QT interval
A KEY ADVERSE DRUG REACTION
In the autumn of 1989, a previously healthy 39-year-old woman was transferred to Bethesda Naval Medical Center after having experienced several episodes of palpitations and near syncope. Her presenting electrocardiogram was very abnormal, displaying a prolonged QT interval with inverted T waves and prominent U waves. Because of the nature of her symptoms and her abnormal ECG, she was placed on a cardiac monitor. In the hours that followed she experienced two more episodes of palpitations, which correlated on telemetry with runs of polymorphic ventricular tachycardia. The occurrence of polymorphic ventricular tachycardia in the setting of a prolonged QT interval fulfilled the definition of torsades de pointes, a syndrome first described in 1966 by the French cardiologist, Dessertenne, most often in association with the use of antiarrhythmic drugs.
Two weeks prior to hospitalisation, the patient had visited her primary care physician complaining of seasonal allergies and sinusitis. She had been given prescriptions for a broad-spectrum antibiotic and for the non-sedating antihistamine terfenadine. After one week of concomitant therapy she felt better but developed Candida vaginitis, a complication of her antibiotic therapy. She was instructed to discontinue her antibiotic, to treat her yeast infection topically and to continue taking terfenadine.
Because her gynaecological symptoms were not improving rapidly enough, she self-medicated with ketOconazole tablets that she found in her medicine cabinet. It is only after 48 hours of concomitant terfenadine and ketOconazole therapy that she developed her cardiac symptoms. Upon admission to the hospital, all her medications were stopped, she had no further episodes of polymorphic ventricular tachycardia and her QT interval normalised. |
Read full article >>
|
 |
 |
 |
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
 |
Jean T Barbey, MD, is Director, Core Laboratory Cardiology at Medifacts and is based in Rockville, Maryland. He acts
as the Core Lab’s internal scientific and medical expert for non-invasive research monitoring. Jean is board-certified
in medicine, cardiology, cardiac electrophysiology and clinical pharmacology, with over 22 years’ clinical research
experience. During his 14-year appointment in the department of Medicine and Pharmacology at Georgetown
University Medical Center, he held positions as Clinical Director of Georgetown University Clinical Research Center,
Director of Holter Laboratory. Jean’s particular area of interest in terms of clinical research has been the acquired
long QT syndrome, and he has published and presented many papers on QT-related topics. |
|
 |
 |
 |
|

 |
Industry Events |
 |
Small Scale Biomanufacturing – clinical trials, cell & gene therapies
18 September 2008, Clifton Pavilion, Bristol Zoo Gardens, Bristol
This one day conference, sponsored by bioProcessUK and organised by BioApproaches South West, will cover key, important topics relating to small scale GMP biomanufacturing.
More info >> |
|
 |
News and Press Releases |
 |
“PACK DIFFERENT” with EMBALLAGE 2008
“Business, Innovation, Outlook” are the watchwords for the 38th World Packaging Exhibition which opens in Paris from 17 to 21 November 2008. Fifteen months before the key packaging event of the end of 2008, EMBALLAGE displays its differences to offer you a new edition that is even more representative, international and rich in new features.
More info >> |
|
|